What Happened to Science.bio? Closure Timeline & Migration Guide

The closure announcement

On January 27, 2026, Science.bio published a closure announcement on its Facebook page (post ID 951466978871034) and emailed the same statement to its customer list. The post described the closure as permanent and confirmed that the company would honor outstanding store credit and pending orders during a wind-down window. The website did not go fully offline at the moment of announcement — instead, the homepage was replaced with a closure banner directing customers to support resources.

This is materially different from how some other 2024–2026 vendor exits have been handled. Where vendors like Peptide Sciences took their site dark with no notice and no refund process, Science.bio published a clear announcement, gave customers a window to use store credit, and continued to serve the closure banner months after the initial post. The community read it as an orderly wind-down, not a regulatory exit.

Closure timeline

• January 27, 2026. Science.bio publishes the permanent-closure announcement on Facebook (post 951466978871034) and via customer email. The site homepage is replaced with a closure banner.
• Late January 2026. The Rapamycin News forum thread aggregates the closure email text and former-customer reactions. The longevity research community begins discussing replacement vendors with comparable catalog coverage.
• February 2026. Outstanding store credit and pending-order refunds are processed during the announced wind-down window.
• Spring 2026 (ongoing). The closure banner remains on science.bio. No successor entity has been announced. The Rapamycin News thread continues to be the primary community-discussion record of the closure.

What the closure email said

We are not republishing the closure email text verbatim — community sources including the Rapamycin News thread linked above contain the original wording. The substance, as documented by former customers in those threads, was:

• The decision to close was permanent, not a pause or rebrand.
• Outstanding store credit would be honored during a defined wind-down window, with refund processing for unused balances.
• Pending orders at the time of announcement would be fulfilled or refunded.
• Customers were directed to community resources for ongoing research questions and to support email for unresolved order issues.

How refunds and store credit were handled

Per the announcement, Science.bio committed to honoring outstanding store credit during a defined wind-down period. Forum reports from late January and February 2026 indicate that most customers received refunds or had pending orders fulfilled within the announced window. For unresolved balances, the announcement directed customers to support email — the community thread above contains former-customer notes on response times and resolution paths. If you have an unresolved Science.bio balance, contact Science.bio support directly; store credit is account-specific and cannot be transferred to another vendor.

Where the longevity research community is going

Science.bio's audience overlapped heavily with the longevity, nootropics, and biohacking research communities — the Rapamycin News forum, r/longevity, r/Nootropics, and independent investigators studying mitochondrial peptides, NAD+ precursors, and selective nootropic peptides. Replacement-vendor discussion in those communities since the closure has converged on three criteria:

• Same compounds. Coverage of the workhorse longevity research molecules — MOTS-c, NAD+, BPC-157, TB-500 — and at least one of the nootropic pair Selank / Semax.
• Same operating posture. Public per-batch COAs, U.S. fulfillment, no marketing of therapeutic outcomes, no GLP-1 weight-loss positioning.
• Comparable price transparency. Per-vial or per-mg pricing on the product page, not gated behind a request form.

Pure U.S. Peptides was built around that posture. We carry the longevity workhorses (MOTS-c, NAD+, BPC-157, TB-500) and the Selank/Semax nootropic pair, with public per-batch COAs and U.S. fulfillment. For a side-by-side comparison, see our companion page on Science.bio alternatives.

How the Science.bio closure compares to other 2024–2026 vendor exits

The 2024–2026 window has produced a steady stream of U.S. research-peptide vendor exits. Each closure has handled customer obligations differently, and the pattern matters when evaluating which replacement vendor to trust with a recurring research order.

• Amino Asylum (June 2025). Forced offline after an FDA warehouse raid. Customers reported lost orders and limited refund recourse. The exit was involuntary and disorderly.
• Peptide Sciences (March 6, 2026). Site went dark with no advance notice. No published refund process. Industry counsel later attributed the closure to FDA enforcement pressure and the proposed SAFE Drugs Act.
• Science.bio (January 27, 2026). Announced permanent closure proactively, honored outstanding store credit and pending orders during a defined wind-down window, and continues to serve a closure banner. The exit was orderly and customer-facing.

For former Science.bio customers, the orderly nature of the closure is a useful signal: the company prioritized resolving customer obligations before it stopped operating. That same posture — clean operating defaults, customer-facing communication, no surprise dark days — is what to look for in a replacement vendor.

What this means for the longevity research community

The Science.bio audience overlapped heavily with the longevity, nootropic, and biohacking research communities. Catalog continuity is the immediate concern: most longevity research projects depend on a small set of compounds (MOTS-c, NAD+, plus one or two of BPC-157 / TB-500 / Selank / Semax), and any supply gap disrupts the research timeline. The wider shift across the U.S. research-peptide segment is a consolidation toward vendors with cleaner positioning: research-use-only labeling on every product page, no therapeutic marketing claims, public per-batch certificates of analysis, and catalogs that avoid the GLP-1 enforcement zone that drove much of the 2024–2026 regulatory pressure.

Pure US Peptide carries the workhorse longevity research compounds Science.bio researchers relied on, with public per-batch COAs and same-day U.S. fulfillment. Our 32-compound catalog is deliberately tighter than Science.bio's — depth over breadth — focused on molecules with deeper published research literature. Side-by-side comparison and full switching guide: /science-bio-alternative.

Migration checklist for former Science.bio customers

1. Resolve any outstanding Science.bio balance through their support email before the wind-down window closes.
2. List the three to five compounds you regularly ordered. Most longevity researchers anchor on MOTS-c + NAD+ plus one or two of BPC-157 / TB-500 / Selank / Semax.
3. Pull the lot-specific COA for each replacement compound from your candidate vendor and verify against your prior Science.bio purity baseline.
4. Run a small first-batch order to validate purity and shipping speed before consolidating your supply. Use a first-order discount where one is offered.
5. Bookmark the closure announcement and forum thread above. If you encounter a domain claiming to be Science.bio under a new URL, treat it as unverified — Science.bio has not announced a successor entity.

Primary sources

• Science.bio Facebook closure post (post ID 951466978871034, January 27, 2026)
• Rapamycin News forum thread — "Science.bio closes"
• science.bio homepage — closure banner served at the time of writing.